Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

Illumina, whose EMEA head office is at Granta Park in Cambridge, has released Illumina Connected Multiomics, a powerful cloud ...

A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.

If you are wondering whether Illumina's current share price offers fair value or room for mispricing, you are not alone. This article walks through what the numbers actually say about the stock.

Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 ...

Aug 13 (Reuters) - Illumina (ILMN.O), opens new tab said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene ...

In May 2024, CGP was incorporated into Taiwan’s National Health Insurance (NHI) program.

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...